BioLife Solutions (BLFS) PT Raised to $31 at TD Cowen

TD Cowen analyst Max Masucci raised the price target on BioLife Solutions (NASDAQ: BLFS) to $31.00 (from $28.00) while maintaining a Buy rating.

The analyst commented, "Core revs of $27M beat consensus driven by Cell Processing strength ($19M, +43% y/ y). Mgmt feels the macro environment is largely normalized driving this segment with 80% of revs coming from top-20 pharma. SciSafe sale for $73M highlights commitment to focus on core competency and high margin rev growth. Raising PT to $31 (+$3) on improved strategy, financial profile, and shored up balance sheet."

You May Also Be Interested In

• TD Cowen Downgrades Flowserve Corp. (FLS) to Hold
• Stifel Canada Starts BlackBerry (BB) at Buy
• argenx SE (ARGX) Reiterated at Market Outperform by Citizens: Ph3 Results on Track for Q3